Test Price
1,100 AEDโ Home Collection Available
Imatinib Resistance Mutation Analysis (IRMA) in UAE | 1100 AED | DHA Compliant
Executive Summary & Core Metrics
Precision-guided Sanger sequencing decodes BCR-ABL kinase domain mutations conferring imatinib resistance in CML and Ph+ ALL. Delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited processing, enabling oncologists to select second- or third-line TKI therapy with confidence.
- Accuracy Guarantee: 99.9% variant detection via high-fidelity Sanger sequencing (>10% variant sensitivity).
- Premium Logistics: VIP Mobile Phlebotomy & temperature-controlled cold-chain home collection available daily 8 AMโ11 PM.
- Clinical Guidance: Complimentary telephonic post-test guidance to contextualize mutational findings for your care team.
- Turnaround Time: 6 days from sample receipt (sample Mon by 11 am, report Sat).
- Insurance & Verification: Direct billing support via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Imatinib Resistance Mutation Analysis (IRMA) is a specialized pharmacogenomic test that sequences the entire BCR-ABL kinase domain to detect point mutations conferring resistance to imatinib and other Tyrosine Kinase Inhibitors (TKIs). The assay uses high-fidelity Sanger sequencing with a sensitivity threshold of 10% variant allele frequency, ensuring clinically relevant resistant clones are identified even at low levels. Results are correlated with the patientโs latest BCR-ABL quantitative report for accurate clinical interpretation.
| Feature | Our Test (ISO-Certified IRMA) | Closest Alternative (Conventional Sequencing) |
|---|---|---|
| Methodological Precision | High-Fidelity Sanger Sequencing with >10% Variant Sensitivity for clinically relevant clones. | May lack the dedicated analytical sensitivity for low-level resistant clones. |
| Clinical Report Speed | 6-Day Dedicated TAT (Sample Mon by 11 am; Report Sat). | Variable, often >10 days due to non-prioritized batch processing. |
| Regulatory Compliance | Full DHA/MOHAP, UAE PDPL, and ISO 9001:2015 compliance. | Compliance status may be unverified or non-localized. |
Physician Insight & Safety Protocols
"The IRMA test is indispensable for managing CML patients who develop resistance to first-line TKIs. Identifying mutations such as T315I or Y253H directly dictates the choice of second- or third-line therapy, and the clinical phase of the disease must be integrated with the mutational profile for optimal outcomes. This analysis turns genomic data into a precise therapeutic roadmap."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Critical Medication Advisory
Do Not Alter TKI Therapy Without Specialist Advice
A negative result for a specific mutation does not rule out all resistance mechanisms. Never discontinue, reduce, or switch your prescribed tyrosine kinase inhibitor based solely on this report. Only your treating oncologist can integrate these findings with your full clinical picture.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Inadequate or clotted samples, failure to provide the latest BCR-ABL Quantitative report, or samples not maintained at refrigerated temperature (DO NOT FREEZE).
- Immediate ER Visit Required: If the patient experiences sudden high fever, uncontrolled bleeding, severe bone pain, or neurological symptoms, these are oncological emergencies unrelated to the test scheduling and require immediate medical attention.
Patient FAQ & Clinical Guidance
1. What exactly does the IRMA test look for, and why is my BCR-ABL report needed?
The IRMA test performs direct DNA sequencing of the BCR-ABL kinase domain to pinpoint specific genetic mutations that cause your current therapy to fail. This information is essential for your doctor to choose the next most effective targeted drug. The BCR-ABL quantitative report provides the baseline molecular response, allowing accurate correlation with your mutational status.
2. When should my oncologist order this resistance mutation analysis?
Your oncologist will typically order this test upon confirmed loss of molecular response, a 5-10 fold rise in BCR-ABL transcripts, or progression to accelerated or blast phase disease, in line with international and DHA guidelines. Early identification of resistance mutations allows timely switching to alternative TKIs.
3. How do I prepare, and what is the home collection process?
A simple, refrigerated 4 mL whole blood draw is all that is required. Our VIP mobile phlebotomy service visits your home between 8 AM and 11 PM, adhering to a strict 'Do Not Freeze' cold-chain protocol from arm to analyzer to guarantee sample validity. Please have your latest BCR-ABL report ready for submission.
UAE Regulatory & Data Privacy Adherence
Your Data, Our Responsibility
DNA Labs UAE operates under the governance of the Dubai Health Authority (DHA) Facility License No. 1143 and complies with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). All genomic data is processed, stored, and transmitted in accordance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) ensures systematic quality management across all laboratory processes.
Clinical & Logistical Metadata
| Attribute | Details |
|---|---|
| Test Name | Imatinib Resistance Mutation Analysis (IRMA) โ BCR-ABL Kinase Domain Sequencing |
| Price (AED) | 1,100 AED |
| Turnaround Time | 6 business days from sample receipt (sample Mon by 11 am, report Sat) |
| Sample Type / Matrix | Whole Blood (Peripheral) โ 4 mL in EDTA tube; refrigerated transport, DO NOT FREEZE |
| Methodology Used | High-Fidelity Sanger Sequencing (PCR + bidirectional sequencing of BCR-ABL kinase domain) |
| ICD-10-CM Code | C92.10 (Chronic myeloid leukemia, BCR/ABL-positive, not in remission); also Z85.6 (Personal history of leukemia) for surveillance |
| LOINC Code | 76057-7 (BCR ABL1 mutation analysis in Blood) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians